(IMVT) – Company Press Releases
-
Immunovant Awarded U.S. Patent for IMVT-1402
-
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
-
Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
-
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
-
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
-
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
-
Immunovant to Present at Upcoming Investor Conferences
-
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023
-
Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Immunovant Announces Pricing of $450 Million Common Stock Financing
-
Immunovant Announces Proposed Offering of $300 Million of Common Stock
-
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
-
Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
-
Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023
-
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023
-
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023
-
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022
-
Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th
-
Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th
-
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022
-
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022
-
Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock
-
Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn
-
Immunovant to Present at Roivant Investor Day on September 28th
-
Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th
-
UPDATE -- Immunovant Announces Two New Development Programs for Batoclimab
-
Immunovant Announces Two New Development Programs for Batoclimab
-
Immunovant to Host Investor Webcast to Announce Two New Indications for Batoclimab on September 7, 2022
-
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended June 30, 2022
-
Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 20
-
Immunovant to Report Fourth Quarter and Full Year 2022 Financial Results on June 8, 2022
-
Immunovant to Present at the H.C. Wainwright Global Investment Conference on May 25th
-
Immunovant to Present at the UBS Global Healthcare Conference on May 23rd
-
Immunovant to Present at LifeSci Partners’ Immunology and Inflammation Symposium on May 10th
-
Immunovant to Host Virtual R&D Day on March 30, 2022
-
Immunovant to Present at the 11th Annual SVB Leerink Global Healthcare Conference
-
Immunovant Reports Financial Results for the Quarter Ended December 31, 2021
-
Immunovant Appoints Mark Levine as Chief Legal Officer
-
Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference
-
Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022
-
Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference
-
Immunovant Reports Financial Results for the Quarter Ended September 30, 2021
-
Immunovant to Participate in Roivant R&D Day 2021
-
Immunovant Appoints Renee Barnett as Chief Financial Officer
-
Immunovant Reports Financial Results for the Quarter Ended June 30, 2021
-
Immunovant to Report Financial Results for Quarter Ended June 30, 2021
-
Immunovant Receives $200 Million Strategic Investment from Roivant Sciences
-
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2021
-
IMVT INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc.
Back to IMVT Stock Lookup